STAAR Surgical Co
Staar Surgical hires consumer marketing expert to move Visian lenses
Staar Surgical (NSDQ:STAA) is looking to take its direct-to-consumer marketing to the next level, hiring commercial branding expert David Choromanski to boost the public profile of the Visian ICL implantable lenses.
Weather-induced FDA delay hits Staar Surgical’s bottom line
California-based STAAR Surgical (NSDQ:STAA) swung hard to a 1st-quarter loss after storm-related regulatory delays cost the company its bottom line.
UPDATE: Staar Surgical jumps on FDA panel nod
An FDA advisory panel voted last week to recommend approval for Staar Surgical‘s (NSDQ:STAA) Visian Toric implantable collamer lens for myopic astigmatism, sending STAA shares up nearly 17% today.
FDA panel recommends approval of Staar Surgical’s novel eye implant
An FDA panel today voted today to recommend approval for Staar Surgical’s (NSDQ:STAA) novel Visian Toric implantable collamer lens for treatment of myopic astigmatism in adults aged 21-45.
STAAR lands new FDA panel date, Japanese approval for implantable lenses
Storm forces postponement of Staar Surgical’s date with FDA panel
A spate of bad weather barreling down on the East Coast today and tomorrow delayed an FDA panel date for Staar Surgical (NSDQ:STAA) and its Toric ICL intraocular implant.
Philips promotes home health chief to North America CEO | Personnel Moves
Staar Surgical’s Toric ICL vision-correcting lens gets a date with the FDA
Staar Surgical swings to Q3 black
Staar Surgical (NSDQ:STAA) put black ink into its ledger for the 3rd quarter, beating Wall Street’s earnigns expectations in the process.